KRRO · Korro Bio, Inc.
$12.96
-0.99 (-7.10%)
At close · Aug 20
Market Cap
$205.42M
Shares
14.73M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.96
Open$13.77
Day$12.83–13.77
52W close$5.28–51.36
Avg vol 30d137K
Short int1.4M · 9.8% float · 9.2d
Short vol70%
Last earningsAug 6, 2026
DataNov 2023–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Nov 6, 2023; bars on opposite sides are not compared.
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+8%
above
Price vs 50-day avg
+4%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
+7%
trailing
YTD return
+62%
this year
Relative strength
−4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $12 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +20 funds added
Insider flow
Distributing
Net -$360.3K over 90 days · 83% sells
Short interest
Falling
9.77% of float · ▼ -1.4% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
107 holders — near 2-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
+181%
Y/Y
EPS growth
−33%
Y/Y
Free cash flow
$-79.1M
Balance sheet
$11.6M
net cash
Quant / Vol
risk profile
Volatility
121%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+8%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
Golden cross
50d $12 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +20 funds added
Insider flow
Distributing
Net -$360.3K over 90 days · 83% sells
Short interest
Falling
9.77% of float · ▼ -1.4% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
107 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $13 · 17%
Range high $51
vs 200-day avg +8%
vs 50-day avg +4%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KRRO
this stock
Korro Bio, Inc.
|
$205.42M | +61.8% | +181.5% | — | 9.8% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Nov 6, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KRRO | -2.5% | +12.4% | +6.8% | +25.0% | +61.8% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -0.5% | +9.1% | -4.3% | +22.9% | +50.0% |
Key facts
CIK
1703647
CUSIP
500946108
13F (30d)
104 filings
102 filers
Visit website
Investor relations